South Korea · Delayed Price · Currency is KRW DongKook Pharmaceutical Company Description
DongKook Pharmaceutical Co., Ltd. produces and sell pharmaceutical products in South Korea and internationally.
The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other processed products.
Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used to protect skin.
In addition, the company develops DKF-424, for the treatment of gastroesophageal reflux disease; DKF-427, used to treat antithrombotic; DKF-460, to treat Dyslipidemia; DKF-5122, for the treatment of Fungal Infection; DKF-MA201 and DKF-MB201, a acromegaly drugs; DKF-MB101, indicated for immunosuppression; and DKF-MA101 and DKF-MA102 to treat prostate cancer.
The company was formerly known as UEC & Co., Ltd. and changed its name to DongKook Pharmaceutical Co., Ltd. in March 1982.
The company was founded in 1968 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 1968 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,183 |
Contact Details
Address: 715 Yeongdong-daero Seoul South Korea | |
| Phone | 82 2 2191 9800 |
| Website | dkpharm.co.kr |
Stock Details
| Ticker Symbol | 086450 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7086450004 |
| SIC Code | 2834 |